Currently, three authorized treatments which are able to increase SMN protein levels are available for SMA patients, namely nusinersen (Spinraza), onasemnogene abeparvovec (Zolgensma), and risdiplam (Evrysdi). The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.